Long-term therapy of multiple basal cell carcinomas: Clinicodermoscopic score for monitoring of intermittent vismodegib treatment.
basal cell carcinoma
dermoscopy
long-term vismodegib treatment
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
29
04
2019
revised:
09
09
2019
accepted:
23
09
2019
pubmed:
16
10
2019
medline:
19
5
2020
entrez:
16
10
2019
Statut:
ppublish
Résumé
Vismodegib treatment of multiple basal cell carcinomas (BCCs) is limited by adverse effects and high relapse rates: intermittent regimens are therefore preferred for long-term administration. The objective of this study was to investigate clinical and dermoscopic changes in BCCs during long-term intermittent treatment and to identify those most indicative of tumor persistence/clearing. Clinical and dermoscopic images (n = 380 each) of 38 BCCs were acquired at 10 observation times (t0-t9). Biopsies were performed at baseline (t0) and after 72 weeks of treatment (t9). All images were evaluated retrospectively by experts who assessed the presence/absence of 12 clinical and 14 dermoscopic features: clinical scores (CScs) and dermoscopic scores (DScs) were then calculated.
Substances chimiques
Anilides
0
HhAntag691
0
Pyridines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13097Informations de copyright
© 2019 Wiley Periodicals, Inc.
Références
Alarcon, I., Pasquali, P., Malvehy, J., & Puig, S. (2017). Tumor regrowth and development of keratinocytic neoplasms in patients under smoothened inhibition: In vivo assessment with reflectance confocal microscopy. Skin Research and Technology, 23, 283-288.
Apalla, Z., Lallas, A., Tzellos, T., Sidiropoulos, T., Lefaki, I., Trakatelli, M., … Ioannides, D. (2014). Applicability of dermoscopy for evaluation of patients' response to nonablative therapies for the treatment of superficial basal cell carcinoma. The British Journal of Dermatology, 170(4), 809-815.
Bichakjian, C. K., Olencki T, Aasi SZ, et al. (2016). Basal cell skin cancer, version 1.2016, NCCN clinical practice guidelines in oncology. Journal of National Comprehensive Cancer Network, 14, 574-597.
Chang, A. L., & Oro, A. E. (2012). Initial assessment of tumor regrowth after Vismodegib in advanced basal cell carcinoma. Archives of Dermatology, 148(11), 1324-1325.
Couzan, C., Cinotti E., Labeille B, et al. (2018). Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after Vismodegib treatment. Journal of the European Academy of Dermatology and Venereology, 32, 763-767.
Cuellar, F., Vilalta, A., Puig, S., Palou, J., Zaballos, P., & Malvey, J. (2008). Dermoscopy of early recurrent basal cell carcinoma. Archives of Dermatology, 144(9), 1254.
Dijkgraaf, G. J. P., Alicke, B., Weinmann, L., Januario, T., West, K., Modrusan, Z., … de Sauvage, F. J. (2011). Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance. Cancer Research, 71(2), 435-444.
Dréno, B., Kunstfeld R., Hauschild A., et al. (2017). Two intermittent Vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): A randomised, regimen-controlled, double-blind, phase 2 trial. The Lancet Oncology, 18, 404-412.
Goldberg, L. H., Landau, J. M., Moody, M. N., Kazakevich, N., Holzer, A. M., & Myers, A. (2011). Resolution of odontogenic keratocysts of the jaw in basal cell nevus syndrome with GDC-0449. Archives of Dermatology, 147, 839-841.
Hansson, J., Hauschild, A., & Kunstfeld, R. (2016). Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in advanced basal cell carcinoma (aBCC): STEVIE study primary analysis in 1215 patients (pts). Journal of Clinical Oncology, 34(15) (abstr 9532).
Lacour, J. P. (2002). Carcinogenesis of basal cell carcinomas: Genetics and molecular mechanisms. The British Journal of Dermatology, 146(S61), 17-19.
Lallas, A., Apalla, Z., Argenziano, G., Longo, C., Moscarella, E., Specchio, F., … Zalaudek, I. (2014). The dermatoscopic universe of basal cell carcinoma. Dermatology Practical and Conceptual, 4(3), 2.
Metcalfe, C., & de Sauvage, F. J. (2011). Hedgehog fights back: Mechanisms of acquired resistance against smoothened antagonists. Cancer Research, 71(15), 5057-5061.
Papageorgiou, C., Apalla, Z., Vakirlis, E., Sotiriou, E., Ioannides, D., & Lallas, A. (2018). Use of dermoscopy to diagnose and select BCCs that can be treated empirically. Current Dermatology Reports, 7(2), 84-90.
Peris, K., Fargnoli, M. C., Garbe, C., Kaufmann, R., Bastholtf, l., Basset, N., … Grob, J. J. (2019). Diagnosis and treatment of basal cell carcinoma: European consensus-based interdisciplinary guidelines. European Journal of Cancer, 118, 10-34.
Sekulic, A., Mangold, A. R., Northfelt, D. W., & LoRusso, P. M. (2013). Advanced basal cell carcinoma of the skin: Targeting the hedgehog pathway. Current Opinion in Oncology, 25, 218-223.
Sekulic, A., Migden, M. R., Oro, A. E., Dirix, L., Lewis, K. D., Hainsworth, J. D., … Hauschild, A. (2012). Efficacy and safety of Vismodegib in advanced basal-cell carcinoma. The New England Journal of Medicine, 366, 2171-2179.
Tang, J. Y., Mackay-Wiggan, J. M., Aszterbaum, M., Yauch, R. L., Lindgren, J., Chan, K., … Epstein, E. H. (2012). Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome. The New England Journal of Medicine, 366, 2180-2188.